Home / Journal / Droopy eyelids and ptosis / Nonsurgical ptosis treatment

Nonsurgical ptosis treatment research

Oxymetazoline and similar eye drops raise a mildly drooping lid for hours by stimulating the Muller muscle without surgery.

33
Papers
26
Since 2021
1
Reviews and meta-analyses
2005
First paper

Papers, newest first

2026
Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study
Ishikawa H, Oka K, Inoue H · Jpn J Ophthalmol · Randomized Controlled Trial · PMID 41961227
2026
Safety Analysis of Oxymetazoline Eye Drops for Blepharoptosis Using the FDA Adverse Event Reporting System
Azzam DB, Hong JD, Chen TH, Alsulaiman YG, Grob SR, Ediriwickrema LS, et al. · Ophthalmic Plast Reconstr Surg · PMID 41949436
2026
2025
Oxymetazoline and Blepharoptosis: A Case Series and Proposed Treatment Algorithm
Brito EM, Ferri F, Odulanmi T, Vera Silva MA, Cordero JP, Foran L, et al. · Cureus · PMID 40861715
2025
Pharmacologic Agents Used in the Assessment or Correction of Blepharoptosis: A Report by the American Academy of Ophthalmology
Grob SR, Tao JP, Aakalu VK, Foster JA, Dagi Glass LR, McCulley TJ, et al. · Ophthalmology · PMID 40172501
2025
The Use of Oxymetazoline 0.1% Ophthalmic Solution for Acquired Blepharoptosis: A Systematic Review
Newland M, Eberly H, Ma C, Lighthall JG · Laryngoscope · Systematic Review · PMID 39172003
2025
Iatrogenic Blepharoptosis: Multimodal Management and Treatment Technique With Botulinum Toxin Type A
Jaime Alberto RP, Paola Andrea MA, Maria Paulina UP, Luisa LB · Dermatol Res Pract · PMID 41142411
2025
Efficacy of Oxymetazoline 0.1% in Acquired Blepharoptosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Bawazir RO, Qedair JT, Bukhari ZM, Badghaish OS, Hubayni RA, Alsudais AS, et al. · Clin Ophthalmol · PMID 40881581
2024
A Breath of Relief: Oxymetazoline and Flunisolide Nasal Spray in the Management of Myasthenia Gravis Ptosis
Aloyan T, Shilleh N, Sharma A, Barsamian B, Sovory L · Cureus · PMID 38784340
2024
A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization
Goldberg DJ, Andriessen A, Gold M, Lolis MS, Marchbein S, Nestor MS, et al. · J Cosmet Dermatol · PMID 38348575
2024
Even Patients Who Respond Poorly to the Phenylephrine Test Can Benefit From Topical Oxymetazoline for Temporary Eyelid Ptosis Management
Ohkawara LE, Osaki MH, Iwakura JH, Gameiro GR, Osaki TH · Ophthalmic Plast Reconstr Surg · PMID 39495666
2024
2023
Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial
Agha M, Ismail H, Sawaya R, Salameh J · Muscle Nerve · PMID 37259693
2023
2023
Management of Severe Botulinum-Induced Eyelid Ptosis With Pretarsal Botulinum Toxin and Oxymetazoline Hydrochloride 0.1
Bernardini FP, Skippen B, Croasdell B, Cerón Bohórquez JM, Murray G, Sayed K, et al. · Aesthet Surg J · PMID 36943792
2023
The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial
Shoji MK, Markatia Z, Ameli K, Bayaraa M, Clauss KD, Ugradar S, et al. · J Plast Reconstr Aesthet Surg · Randomized Controlled Trial · PMID 36996503
2023
2023
About the pathways to deliver brimonidine to the Muller's muscle
Ghanian S, Wambier SPF, Procianoy F, Wambier CG · JAAD Case Rep · PMID 36785538
2022
Uses of eye drops in dermatology, literature review
Sarsik SM, El-Amawy HS · J Dermatolog Treat · PMID 35652324
2022
2022
Changes to Eye Whiteness and Eyelid/Brow Position With Topical Oxymetazoline in Aesthetic Patients
Ugradar S, Kim JS, Trost N, Parunakian E, Zimmerman E, Ameli K, et al. · Aesthet Surg J · PMID 34962512
2022
Apraclonidine-An eye opener
Fierz FC, Disse LR, Bockisch CJ, Weber KP · Front Ophthalmol (Lausanne) · PMID 38983513
2021
Case Report: Treatment of Myasthenic Ptosis with Topical Ocular Oxymetazoline
Cooper J, Yang D · Optom Vis Sci · PMID 34510144
2021
Botulinum toxin-induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options
Nestor MS, Han H, Gade A, Fischer D, Saban Y, Polselli R · J Cosmet Dermatol · PMID 34378298
2021
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, et al. · Clin Ophthalmol · PMID 34675472
2021
Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, et al. · Clin Ophthalmol · PMID 34211263
2020
Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials
Slonim CB, Foster S, Jaros M, Kannarr SR, Korenfeld MS, Smyth-Medina R, et al. · JAMA Ophthalmol · PMID 33001144
2020
Oxymetazoline for Ptosis
Bradley EA, Bradley DJ · JAMA Ophthalmol · PMID 33001145
2018
Distribution of Adrenergic Receptor Subtypes and Responses to Topical 0.5% Apraclonidine in Patients With Blepharoptosis
Park SJ, Jang SY, Baek JS, Chin S, Jang JW · Ophthalmic Plast Reconstr Surg · PMID 29634605
2017
Apraclonidine in the treatment of ptosis
Wijemanne S, Vijayakumar D, Jankovic J · J Neurol Sci · PMID 28431598
2017
Treatment of blepharospasm with apraclonidine
Vijayakumar D, Wijemanne S, Jankovic J · J Neurol Sci · PMID 28017248
2008
Use of 0.5% apraclonidine solution in evaluation of blepharoptosis
Yazici B, Beden U · Ophthalmic Plast Reconstr Surg · PMID 18645436
2005